Shares of Tobira Therapeutics Inc. (NASDAQ:TBRA) dropped 1.2% during mid-day trading on Friday . The company traded as low as $4.93 and last traded at $5.02, with a volume of 71,122 shares traded. The stock had previously closed at $5.08.

TBRA has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of Tobira Therapeutics from a “hold” rating to a “strong-buy” rating and set a $9.25 price target for the company in a research report on Thursday, May 5th. HC Wainwright restated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, June 28th. Leerink Swann restated a “buy” rating and issued a $18.00 price objective on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Cowen and Company restated a “buy” rating on shares of Tobira Therapeutics in a report on Tuesday, May 10th. Finally, Cantor Fitzgerald downgraded Tobira Therapeutics to a “buy” rating and set a $19.00 price objective on the stock. in a report on Monday, July 25th. Five analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and a consensus price target of $16.75.

The stock’s market cap is $96.74 million. The company has a 50-day moving average price of $5.83 and a 200-day moving average price of $8.19.

Tobira Therapeutics (NASDAQ:TBRA) last posted its earnings results on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.63) by $0.08. The firm earned $1.06 million during the quarter. Analysts expect that Tobira Therapeutics Inc. will post ($2.65) EPS for the current fiscal year.

In other news, major shareholder A/S Novo sold 66,814 shares of the business’s stock in a transaction dated Thursday, June 30th. The stock was sold at an average price of $13.04, for a total transaction of $871,254.56. Following the completion of the transaction, the insider now directly owns 2,073,022 shares in the company, valued at approximately $27,032,206.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Tobira Therapeutics, Inc, formerly Regado Biosciences, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat liver disease, inflammation, fibrosis and human immunodeficiency virus (HIV). The Company’s lead product candidate, cenicriviroc (CVC), is an immunomodulator and dual inhibitor of C-C Chemokine Receptor 2 (CCR2) and C-C Chemokine Receptor 5 (CCR5) being evaluated for the treatment of non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and as an adjunctive therapy to standard of care in HIV.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.